Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer

(Yates Public Relations) Agios Pharmaceuticals scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. The mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate, which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers, through altered metabolic activity. This discovery appears to reverse the previously held belief that IDH1 was non functional for cancer-causing activity.

source : www.eurekalert.org

Related News:

• Kidney Cancer Drug Shows Promising Results
• Launch Of Ipsen’s Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Prostate Cancer
• Barker Hypothesis Strengthened By Ancient Tooth Remains
• Scientists At Rice University Discover That ‘Nanobubbles’ Kill Cancer
• AM: Opioid Gains Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Launch Of Ipsen’s Decapeptyl 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Advanced Or Metastatic Hormone-Dependent Prostate Cancer
• Green Tea Extracts Halt Growth of Prostate Cancer Tumors
• AM: Opioid Shows Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Recordati : Silodosin Approved By The European Commission For The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia
• EMEA Gives Official Scientific Advice On Clinical Phase IIb Efficacy Study Of Inecalcitol In Hormone-refractory Prostate Cancer

Details :
Submited at Sunday, November 22nd, 2009 at 7:00 pm on Cancer and Oncology by chuck
Comment RSS 2.0 - leave a comment - trackback